Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell homing refers to the highly regulated process governing the migration of T lymphocytes from the bloodstream to specific tissues, determined by expression of surface receptors such as selectins, integrins, and chemokine receptors. These molecules interact with ligands on vascular endothelium, guiding T-cell entry into lymphoid organs, inflamed tissues, or tumors. The process is essential for normal immune surveillance, adaptive responses, and, in pathology, influences the development and outcome of inflammation, autoimmunity, cancer, and infection. Drugs targeting components of the homing machinery have clinical relevance for treating autoimmune diseases, inflammatory bowel disease, and certain cancers.
Blockade of homing receptors to prevent T-cell entry to tissue; Modulation of chemokine receptor signaling; Inhibition of integrin-mediated adhesion
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell homing.